Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Dogwood Therapeutics Inc (DWTX)

Dogwood Therapeutics Inc (DWTX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 15,640
  • Shares Outstanding, K 2,293
  • Annual Sales, $ 0 K
  • Annual Income, $ -12,350 K
  • EBIT $ -32 M
  • EBITDA $ -32 M
  • 60-Month Beta 1.86
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book N/A

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 2 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate -1.22
  • Number of Estimates 2
  • High Estimate -0.44
  • Low Estimate -2.00
  • Prior Year -6.29
  • Growth Rate Est. (year over year) +80.60%

Price Performance

See More
Period Period Low Period High Performance
1-Month
5.10 +33.72%
on 11/14/25
7.04 -3.17%
on 12/12/25
+0.99 (+16.98%)
since 11/12/25
3-Month
4.77 +42.98%
on 09/15/25
9.50 -28.21%
on 09/29/25
+1.93 (+39.47%)
since 09/12/25
52-Week
1.87 +264.71%
on 01/17/25
29.28 -76.71%
on 01/23/25
+4.41 (+182.99%)
since 12/12/24

Most Recent Stories

More News
Dogwood Therapeutics Reports Third Quarter 2025 Financial Results

- Enrollment to date of 100 patients, with 80 patients completing treatment in the ongoing Halneuron ® Phase 2b trial, prespecified interim analysis remains on track for Q4 2025 release - - Secured...

DWTX : 6.82 (+6.23%)
Dogwood Therapeutics Announces Business Combination Plans

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Dogwood Therapeutics...

DWTX : 6.82 (+6.23%)
Dogwood Therapeutics Secures Exclusive Worldwide, Royalty Free License to Develop and Commercialize SP16 as a Treatment for Cancer Related Pain in an All-Stock Transaction Underscoring the Company’s Dedication to Improving the Lives of Cancer...

-A first-in-class LRP1 agonist, SP16 phase 1b Chemotherapy Induced Neuropathy (CIPN) Study fully funded by the National Cancer Institute, with projected patient enrollment beginning in the first half...

DWTX : 6.82 (+6.23%)
Dogwood Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference

ATLANTA, Sept. 03, 2025 (GLOBE NEWSWIRE) --  Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development-stage biotechnology company developing new medicines to treat pain and fatigue-related...

DWTX : 6.82 (+6.23%)
Dogwood Therapeutics Reports Second Quarter 2025 Financial Results

- Enrollment to-date of 52 patients in the ongoing Halneuron ® Phase 2b Trial - - Halneuron ® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track...

DWTX : 6.82 (+6.23%)
Dogwood Therapeutics Announces Enrollment of First Fifty Patients in Ongoing Halneuron® Phase 2b Trial

- Halneuron ® Chemotherapy-Induced Neuropathic Pain (“CINP”) Phase 2b study interim data readout remains on track as projected for Q4 2025 - - Low discontinuation rate (6%) due to adverse events...

DWTX : 6.82 (+6.23%)
Dogwood Therapeutics to Report Second Quarter 2025 Financial Results on Wednesday, August 13, 2025

ATLANTA, Aug. 06, 2025 (GLOBE NEWSWIRE) -- Dogwood Therapeutics, Inc. (Nasdaq: DWTX) (the “Company”), a development‐stage biotechnology company developing new medicines to treat pain and fatigue-related...

DWTX : 6.82 (+6.23%)
Dogwood Therapeutics to Present at Sidoti Small-Cap Virtual Conference

DWTX : 6.82 (+6.23%)
Dogwood Therapeutics Announces First Quarter 2025 Financial Results

DWTX : 6.82 (+6.23%)
Dogwood Therapeutics, Inc. Announces Participation in the D. Boral Capital Inaugural Global Conference

Alpharetta, Georgia--(Newsfile Corp. - May 1, 2025) - Dogwood Therapeutics, Inc. (NASDAQ: DWTX), today announced its participation in the D. Boral Capital Inaugural Global Conference, taking place May...

DWTX : 6.82 (+6.23%)

Business Summary

Dogwood Therapeutics Inc. is a biopharmaceutical company. It engages in developing a new class of non-opioid analgesics. The company focuses on the development of Halneuron, IMC-1 and IMC-2. Dogwood Therapeutics Inc., formerly known as Virios Therapeutics Inc., is based in Alpharetta, GA.

See More

Key Turning Points

3rd Resistance Point 7.79
2nd Resistance Point 7.41
1st Resistance Point 7.12
Last Price 6.82
1st Support Level 6.45
2nd Support Level 6.08
3rd Support Level 5.78

See More

52-Week High 29.28
Fibonacci 61.8% 18.81
Fibonacci 50% 15.58
Fibonacci 38.2% 12.34
Last Price 6.82
52-Week Low 1.87

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar